Pediatric Nephrology

, Volume 20, Issue 3, pp 290–294

Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure

Review

Abstract

Renal disease in children disrupts the growth hormone (GH) and insulin-like growth factor (IGF) axis and causes growth failure. Although GH therapy stimulates growth in these children, their short stature is likely due to a form of IGF-1 deficiency (IGFD) rather than GH deficiency. Recent experimental data have caused us to reconsider the importance of IGF-1 and IGFD to human growth. Pharmacology studies in rodents, as well as studies in patients with no functional GH receptors and primary IGFD, have shown that IGF-1 is an effective growth-promoting therapy. Gene knockout studies in mice have shown that IGF-1, rather than GH, is the major hormone controlling growth. In addition, both pharmacological and genetic studies have shown that there are effects of GH and IGF-1 that require their combined presence. In children with primary IGFD, where there is no GH signaling, recombinant human (rh)IGF-1 produces a large growth response, while in children who are GH and IGF-1 deficient, treatment with rhGH is the most-appropriate therapy. Children with short stature due to renal failure are GH sufficient and have some GH receptor signaling capacity, so that rhIGF-1, or rhIGF-1 plus rhGH, are logical therapeutic options and merit clinical testing.

Keywords

Insulin-like growth factor-1 Growth hormone Combination therapy Short stature Renal failure 

References

  1. 1.
    Daughaday WH (1989) A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity. Perspect Biol Med 32:194–211Google Scholar
  2. 2.
    Salmon WD Jr, Daughaday WH (1990) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 116:408–419Google Scholar
  3. 3.
    Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253:2769–2776Google Scholar
  4. 4.
    Isaksson OG, Jansson JO, Gause IA (1982) Growth hormone stimulates longitudinal bone growth directly. Science 216:1237–1239Google Scholar
  5. 5.
    Isaksson OG, Lindahl A, Nilsson A, Isgaard J (1987) Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 8:426–438Google Scholar
  6. 6.
    Skottner A, Clark RG, Robinson IC, Fryklund L (1987) Recombinant human insulin-like growth factor: testing the somatomedin hypothesis in hypophysectomized rats. J Endocrinol 112:123–132Google Scholar
  7. 7.
    Laron Z (1999) The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 84:4397–4404Google Scholar
  8. 8.
    Mehls O, Schaefer F, Tonshoff B (2003) Growth disorders in chronic renal failure. Oxford PharmaGenesis, Oxford, pp 1–119Google Scholar
  9. 9.
    Powell-Braxton L, Hollingshead P, Giltinan D, Pitts-Meek S, Stewart T (1993) Inactivation of the IGF-I gene in mice results in perinatal lethality. Ann N Y Acad Sci 692:300–301Google Scholar
  10. 10.
    Liu JL, Yakar S, LeRoith D (2000) Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med 223:344–351Google Scholar
  11. 11.
    Woods KA, Camacho-Hubner C, Savage MO, Clark AJ (1996) Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363–1367CrossRefPubMedGoogle Scholar
  12. 12.
    Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C (1999) Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088–7092Google Scholar
  13. 13.
    Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324–7329Google Scholar
  14. 14.
    LeRoith D, Bondy C, Yakar S, Liu J-L, Butler A (2001) The somatomedin hypothesis: 2001. Endocr Rev 22:53–74CrossRefPubMedGoogle Scholar
  15. 15.
    Clark RG, Robinson IC (1996) Up and down the growth hormone cascade. Cytokine Growth Factor Rev 7:65–80Google Scholar
  16. 16.
    Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854CrossRefPubMedGoogle Scholar
  17. 17.
    Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D (2002) Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771–781CrossRefPubMedGoogle Scholar
  18. 18.
    Tonshoff B, Blum WF, Wingen AM, Mehls O (1995) Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 80:2684–2691CrossRefPubMedGoogle Scholar
  19. 19.
    Tonshoff B, Veldhuis JD, Heinrich U, Mehls O (1995) Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease. Pediatr Res 37:86–93Google Scholar
  20. 20.
    Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A (2001) Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 229:141–162CrossRefPubMedGoogle Scholar
  21. 21.
    Clark RG, Mortensen DL, Carlsson LMS (1995) Insulin-like growth factor-1 and growth hormone (GH) have distinct and overlapping anabolic effects in GH-deficient rats. Endocrine 3:297–304Google Scholar
  22. 22.
    Clark RG, Thomas GB, Mortensen DL, Won WB, Ma YH, Tomlinson EE, Fairhall KM, Robinson IC (1997) Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 138:4316–4323Google Scholar
  23. 23.
    Rosenfeld RG (1996) Biochemical diagnostic strategies in the evaluation of short stature: the diagnosis of insulin-like growth factor deficiency. Horm Res 46:170–173Google Scholar
  24. 24.
    Attie KM, Carlsson LM, Rundle AC, Sherman BM (1995) Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr 127:244–250Google Scholar
  25. 25.
    Rogol AD, Blethen SL, Sy JP, Veldhuis JD (2003) Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy? Clin Endocrinol (Oxf) 58:229–237Google Scholar
  26. 26.
    Hazel SJ, Gillespie CM, Moore RJ, Clark RG, Jureidini KF, Martin AA (1994) Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination. Kidney Int 46:58–68Google Scholar
  27. 27.
    Kovacs GT, Oh J, Kovacs J, Tonshoff B, Hunziker EB, Zapf J, Mehls O (1996) Growth promoting effects of growth hormone and IGF-I are additive in experimental uremia. Kidney Int 49:1413–1421PubMedGoogle Scholar
  28. 28.
    Vijayan A, Franklin SC, Behrend T, Hammerman MR, Miller SB (1999) Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol 276:R929–R934Google Scholar
  29. 29.
    Guler HP, Schmid C, Zapf J, Froesch ER (1989) Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86:2868–2872Google Scholar

Copyright information

© IPNA 2005

Authors and Affiliations

  1. 1.TercicaSouth San FranciscoUSA

Personalised recommendations